DURABLE REMISSIONS WITH CONTROL OF CYTOKINE RELEASE SYNDROME (CRS) USING T CELLS EXPRESSING CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) CTL019 TO TREAT RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOID LEUKEMIA (ALL)

被引：1

作者：

Levine, B. L. ^{[1
,2
,3
]}

Maude, S. ^{[4
,5
,6
]}

Zheng, Z. ^{[1
,2
]}

Shaw, P. ^{[7
]}

Ambrose, D. ^{[1
]}

Aplenc, R. ^{[5
,6
]}

Barker, C. ^{[4
,5
,6
]}

Barrett, D. ^{[4
,5
,6
]}

Brogdon, J. ^{[8
]}

Callahan, C. ^{[5
,6
]}

Chen, F. ^{[1
]}

Chew, A. ^{[1
]}

Davis, M. M. Suhoski ^{[1
,2
]}

Fesnak, A. D. ^{[1
,2
]}

Finklestein, J. ^{[1
]}

Frey, N. ^{[8
]}

Lacey, S. ^{[1
]}

Lamontagne, A. ^{[1
,2
]}

Lewitt, L. ^{[1
,2
]}

Loew, A. ^{[8
]}

Marcucci, K. ^{[1
]}

Melenhorst, J. ^{[1
,2
]}

Motley, L. ^{[5
,6
]}

Mudambi, M. ^{[5
,6
]}

Nazimuddin, F. ^{[1
]}

O'Rourke, M. ^{[1
,2
]}

Porter, D. ^{[3
]}

Rheingold, S. R. ^{[5
,6
]}

Scholler, J. ^{[1
]}

Tayor, C. ^{[1
,2
]}

White, C. ^{[5
,6
]}

Wood, P. ^{[9
]}

Young, R. ^{[1
]}

Teachey, D. T. ^{[4
,5
,6
]}

June, C. ^{[1
,2
,3
]}

Grupp, S. ^{[3
,4
,5
,6
]}

机构：

[1] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[2] Univ Penn, Pathol & Lab Med, Philadelphia, PA 19104 USA

[3] Abramson Canc Ctr, Philadelphia, PA USA

[4] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA

[5] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[6] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA

[7] Univ Penn, Biostat & Epidemiol, Philadelphia, PA 19104 USA

[8] Novartis Inst Biomed Res, Cambridge, MA USA

[9] Novartis Pharmaceut, Cell & Gene Therapies Unit, E Hanover, NJ USA

来源：

CYTOTHERAPY | 2016年 / 18卷 / 06期

关键词：

D O I：

10.1016/j.jcyt.2016.03.039

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

引用

页码：S14 / S15

页数：2

共 50 条

[41] Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)
Teachey, D.
Lacey, S.
Shaw, P.
Melenhorst, J. J.
Maude, S.
Frey, N.
Pequignot, E.
Chen, F.
Gonzalez, V.
Barrett, D.
June, C.
Porter, D.
Grupp, S.
PEDIATRIC BLOOD & CANCER, 2016, 63 : S8 - S8
[42] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Wang, Yiyun
Yang, Yingying
Hong, Ruimin
Zhao, Houli
Wei, Guoqing
Wu, Wenjun
Xu, Huijun
Cui, Jiazhen
Zhang, Yanlei
Chang, Alex H.
Hu, Yongxian
Huang, He
BLOOD CANCER JOURNAL, 2020, 10 (10)
[43] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Yiyun Wang
Yingying Yang
Ruimin Hong
Houli Zhao
Guoqing Wei
Wenjun Wu
Huijun Xu
Jiazhen Cui
Yanlei Zhang
Alex H. Chang
Yongxian Hu
He Huang
Blood Cancer Journal, 10
[44] Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL
Porter, David L.
Frey, Noelle V.
Melenhorst, Jan J.
Hwang, Wei-Ting
Lacey, Simon F.
Shaw, Pamela A.
Chew, Anne
Marcucci, Katherine
Gill, Saar
Loren, Alison W.
Mato, Anthony R.
Schuster, Stephen J.
Lledo, Lester
McConville, Holly
Gilmore, Joan
Capobianchi, James
Kalos, Michael D.
Grupp, Stephan A.
Levine, Bruce
June, Carl H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[45] Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART 19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses
Grupp, Stephan A.
Kalos, Michael
Barrett, David M.
Teachey, David T.
Levine, Bruce
Milone, Michael
Porter, David
June, Carl H.
CANCER RESEARCH, 2013, 73 (08)
[46] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
Tu, Sanfang
Zhou, Lijuan
Huang, Rui
Zhou, Xuan
Yang, Jilong
Li, Meifang
Jin, Bo
Wang, Langqi
Zhuo, Yaqi
Chen, Huifang
Chang, Lung-Ji
Li, Yuhua
BLOOD, 2023, 142
[47] Metabolic tumor burden and cytokine release syndrome (CRS) in patients with diffuse large cell B lymphoma (DLCBL) treated with CTL019 chimeric antigen receptor -T-cell (CAR-T): preliminary experience
Mantarro, C.
Donegani, M.
Bauckneht, M.
Raffa, S.
Chiola, S.
Miceli, A. A.
Lanfranchi, F.
D'Amico, F.
Sambuceti, G.
Raiola, A.
Ghiggi, C.
Angelucci, E.
Morbelli, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S540 - S540
[48] Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Maude, Shannon L.
Barrett, David M.
Rheingold, Susan R.
Aplenc, Richard
Teachey, David T.
Callahan, Colleen
Baniewicz, Diane
White, Claire
Talekar, Mala K.
Shaw, Pamela A.
Brogdon, Jennifer L.
Young, Regina M.
Scholler, John
Marcucci, Katherine T.
Levine, Bruce L.
Frey, Noelle
Porter, David L.
Lacey, Simon F.
Melenhorst, J. Joseph
June, Carl H.
Grupp, Stephan A.
BLOOD, 2016, 128 (22)
[49] CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity
Stein, Andrew M.
Grupp, Stephan A.
Levine, John E.
Laetsch, Theodore W.
Pulsipher, Michael A.
Boyer, Michael W.
August, Keith J.
Levine, Bruce L.
June, Carl H.
Tomassian, Lori
Shah, Sweta
Leung, Mimi
Huang, Pai-Hsi
Jolivet, Sebastien
Awasthi, Rakesh
Mueller, Karen Thudium
Wood, Patricia A.
Maude, Shannon L.
BLOOD, 2017, 130
[50] Cerebral cytokine release syndrome and complete remission of acute leukemia after CD19 chimeric antigen receptor modified T cell therapy
Hu, Y.
Wu, Z.
Sun, J.
Yu, J.
Pu, C.
Xiao, L.
Huang, H.
BONE MARROW TRANSPLANTATION, 2016, 51 : S324 - S325

← 1 2 3 4 5 →